-
1
-
-
0037115195
-
All-trans retinoic acid in acute promyelocytic leukemia: Long-term outcome and prognostic factor analysis from the North American Intergroup protocol
-
Tallman MS, Andersen JW, Schiffer CA, et al: All-trans retinoic acid in acute promyelocytic leukemia: Long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood 100:4298-4302, 2002
-
(2002)
Blood
, vol.100
, pp. 4298-4302
-
-
Tallman, M.S.1
Andersen, J.W.2
Schiffer, C.A.3
-
2
-
-
34347386848
-
A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML-RARalpha transcript after consolidation therapy: The Japan Adult Leukemia Study Group (JALSG) APL97 study
-
Asou N, Kishimoto Y, Kiyoi H, et al: A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML-RARalpha transcript after consolidation therapy: The Japan Adult Leukemia Study Group (JALSG) APL97 study. Blood 110:59-66, 2007
-
(2007)
Blood
, vol.110
, pp. 59-66
-
-
Asou, N.1
Kishimoto, Y.2
Kiyoi, H.3
-
3
-
-
74049115852
-
High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: Long-term results of the German AMLCG
-
Lengfelder E, Haferlach C, Saussele S, et al: High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: Long-term results of the German AMLCG. Leukemia 23:2248-2258, 2009
-
(2009)
Leukemia
, vol.23
, pp. 2248-2258
-
-
Lengfelder, E.1
Haferlach, C.2
Saussele, S.3
-
4
-
-
77950361899
-
Very longterm outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: The European APL Group experience
-
Adès L, Guerci A, Raffoux E, et al: Very longterm outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: The European APL Group experience. Blood 115:1690-1696, 2010
-
(2010)
Blood
, vol.115
, pp. 1690-1696
-
-
Adès, L.1
Guerci, A.2
Raffoux, E.3
-
5
-
-
77954681398
-
Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: Further improvements in treatment outcome
-
Sanz MA, Montesinos P, Rayón C, et al: Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: Further improvements in treatment outcome. Blood 115:5137-5146, 2010
-
(2010)
Blood
, vol.115
, pp. 5137-5146
-
-
Sanz, M.A.1
Montesinos, P.2
Rayón, C.3
-
6
-
-
79955991053
-
AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: Very long-term results and role of maintenance
-
Avvisati G, Lo-Coco F, Paoloni FP, et al: AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: Very long-term results and role of maintenance. Blood 117:4716-4725, 2011
-
(2011)
Blood
, vol.117
, pp. 4716-4725
-
-
Avvisati, G.1
Lo-Coco, F.2
Paoloni, F.P.3
-
7
-
-
84856501661
-
Results of the APML3 trial incorporating all-transretinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia
-
Iland H, Bradstock K, Seymour J, et al: Results of the APML3 trial incorporating all-transretinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia. Haematologica 97:227-234, 2012
-
(2012)
Haematologica
, vol.97
, pp. 227-234
-
-
Iland, H.1
Bradstock, K.2
Seymour, J.3
-
8
-
-
84876120195
-
Inclusion of chemotherapy in addition to anthracycline in the treatment of acute promyelocytic leukaemia does not improve outcomes: Results of the MRC AML15 trial
-
Burnett AK, Hills RK, Grimwade D, et al: Inclusion of chemotherapy in addition to anthracycline in the treatment of acute promyelocytic leukaemia does not improve outcomes: Results of the MRC AML15 trial. Leukemia 27:843-851, 2013
-
(2013)
Leukemia
, vol.27
, pp. 843-851
-
-
Burnett, A.K.1
Hills, R.K.2
Grimwade, D.3
-
9
-
-
61949441174
-
Management of acute promyelocytic leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet
-
Sanz MA, Grimwade D, Tallman MS, et al: Management of acute promyelocytic leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 113:1875-1891, 2009
-
(2009)
Blood
, vol.113
, pp. 1875-1891
-
-
Sanz, M.A.1
Grimwade, D.2
Tallman, M.S.3
-
10
-
-
41949111045
-
Acute promyelocytic leukemia: From highly fatal to highly curable
-
Wang ZY, Chen Z: Acute promyelocytic leukemia: From highly fatal to highly curable. Blood 111:2505-2515, 2008
-
(2008)
Blood
, vol.111
, pp. 2505-2515
-
-
Wang, Z.Y.1
Chen, Z.2
-
11
-
-
77956249684
-
Therapy-related myeloid neoplasms in patients with acute promyelocytic leukemia treated with all-transretinoic acid and anthracycline-based chemotherapy
-
Montesinos P, González JD, González J, et al: Therapy-related myeloid neoplasms in patients with acute promyelocytic leukemia treated with all-transretinoic acid and anthracycline-based chemotherapy. J Clin Oncol 28:3872-3879, 2010
-
(2010)
J Clin Oncol
, vol.28
, pp. 3872-3879
-
-
Montesinos, P.1
González, J.D.2
González, J.3
-
12
-
-
84865074686
-
The cell biology of disease: Acute promyelocytic leukemia, arsenic, and PML bodies
-
de Thé H, Le Bras M, Lallemand-Breitenbach V: The cell biology of disease: Acute promyelocytic leukemia, arsenic, and PML bodies. J Cell Biol 198:11-21, 2012
-
(2012)
J Cell Biol
, vol.198
, pp. 11-21
-
-
De Thé, H.1
Le Bras, M.2
Lallemand-Breitenbach, V.3
-
13
-
-
84878562951
-
Treatment of acute promyelocytic leukemia with single-agent arsenic trioxide
-
Mathews V, Chendamarai E, George B, et al: Treatment of acute promyelocytic leukemia with single-agent arsenic trioxide. Mediterr J Hematol Infect Dis 3:e2011056, 2011
-
(2011)
Mediterr J Hematol Infect Dis
, vol.3
-
-
Mathews, V.1
Chendamarai, E.2
George, B.3
-
14
-
-
84860111877
-
Arsenic trioxide for management of acute promyelocytic leukemia: Current evidence on its role in front-line therapy and recurrent disease
-
Breccia M, Lo-Coco F: Arsenic trioxide for management of acute promyelocytic leukemia: Current evidence on its role in front-line therapy and recurrent disease. Expert Opin Pharmacother 13:1031-1043, 2012
-
(2012)
Expert Opin Pharmacother
, vol.13
, pp. 1031-1043
-
-
Breccia, M.1
Lo-Coco, F.2
-
15
-
-
0000531696
-
Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells
-
Shao W, Fanelli M, Ferrara FF, et al: Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells. J Natl Cancer Inst 90:124-133, 1998
-
(1998)
J Natl Cancer Inst
, vol.90
, pp. 124-133
-
-
Shao, W.1
Fanelli, M.2
Ferrara, F.F.3
-
16
-
-
79960225126
-
Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia
-
Ghavamzadeh A, Alimoghaddam K, Rostami S, et al: Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia. J Clin Oncol 29:2753-2757, 2011
-
(2011)
J Clin Oncol
, vol.29
, pp. 2753-2757
-
-
Ghavamzadeh, A.1
Alimoghaddam, K.2
Rostami, S.3
-
17
-
-
33645498328
-
Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: Durable remissions with minimal toxicity
-
Mathews V, George B, Lakshmi KM, et al: Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: Durable remissions with minimal toxicity. Blood 107:2627-2632, 2006
-
(2006)
Blood
, vol.107
, pp. 2627-2632
-
-
Mathews, V.1
George, B.2
Lakshmi, K.M.3
-
18
-
-
33646386643
-
Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia
-
Estey E, Garcia-Manero G, Ferrajoli A, et al: Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood 107:3469-3473, 2006
-
(2006)
Blood
, vol.107
, pp. 3469-3473
-
-
Estey, E.1
Garcia-Manero, G.2
Ferrajoli, A.3
-
19
-
-
59149089411
-
Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin
-
Ravandi F, Estey E, Jones D, et al: Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol 27:504-510, 2009
-
(2009)
J Clin Oncol
, vol.27
, pp. 504-510
-
-
Ravandi, F.1
Estey, E.2
Jones, D.3
-
20
-
-
84880287051
-
Retinoic acid and arsenic trioxide for acute promyelocytic leukemia
-
Lo-Coco F, Avvisati G, Vignetti M, et al: Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med 369:111-121, 2013
-
(2013)
N Engl J Med
, vol.369
, pp. 111-121
-
-
Lo-Coco, F.1
Avvisati, G.2
Vignetti, M.3
-
21
-
-
84948978098
-
Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): Results of a randomised, controlled, phase 3 trial
-
Burnett AK, Russell NH, Hills RK, et al: Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): Results of a randomised, controlled, phase 3 trial. Lancet Oncol 16:1295-1305, 2015
-
(2015)
Lancet Oncol
, vol.16
, pp. 1295-1305
-
-
Burnett, A.K.1
Russell, N.H.2
Hills, R.K.3
-
23
-
-
84907806243
-
A Canadian consensus on the management of newly diagnosed and relapsed acute promyelocytic leukemia in adults
-
Seftel MD, Barnett MJ, Couban S, et al.: A Canadian consensus on the management of newly diagnosed and relapsed acute promyelocytic leukemia in adults. Curr Oncol 21:234-250, 2014
-
(2014)
Curr Oncol
, vol.21
, pp. 234-250
-
-
Seftel, M.D.1
Barnett, M.J.2
Couban, S.3
-
24
-
-
59649106888
-
Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: Characteristics, outcome, and prognostic factors
-
Montesinos P, Bergua JM, Vellenga E, et al: Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: Characteristics, outcome, and prognostic factors. Blood 113:775-783, 2009
-
(2009)
Blood
, vol.113
, pp. 775-783
-
-
Montesinos, P.1
Bergua, J.M.2
Vellenga, E.3
-
25
-
-
0026647140
-
The "retinoic acid syndrome" in acute promyelocytic leukemia
-
Frankel SR, Eardley A, Lauwers G, et al: The "retinoic acid syndrome" in acute promyelocytic leukemia. Ann Intern Med 117:292-296, 1992
-
(1992)
Ann Intern Med
, vol.117
, pp. 292-296
-
-
Frankel, S.R.1
Eardley, A.2
Lauwers, G.3
-
26
-
-
84908406763
-
Randomized phase III trial of retinoic acid and arsenic trioxide versus retinoic acid and chemotherapy in patients with acute promyelocytic leukemia: Health-related quality-of-life outcomes
-
Efficace F, Mandelli F, Avvisati G, et al: Randomized phase III trial of retinoic acid and arsenic trioxide versus retinoic acid and chemotherapy in patients with acute promyelocytic leukemia: Health-related quality-of-life outcomes. J Clin Oncol 32:3406-3412, 2014
-
(2014)
J Clin Oncol
, vol.32
, pp. 3406-3412
-
-
Efficace, F.1
Mandelli, F.2
Avvisati, G.3
|